Patents by Inventor Rose A. Persichetti

Rose A. Persichetti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8765723
    Abstract: This invention relates to novel compounds which are derivatives of the phosphodiesterase inhibitor, cilostazol and pharmaceutically acceptable salts thereof. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administration of a phosphodiesterase inhibitor, such as cilostazol. The invention also relates to the use of the disclosed compounds and compositions as reagents in analytical studies involving cilostazol.
    Type: Grant
    Filed: January 7, 2013
    Date of Patent: July 1, 2014
    Assignee: CoNCERT Pharmaceuticals, Inc.
    Inventors: Rose A. Persichetti, Julie F. Liu, Craig E. Masse, Scott L. Harbeson
  • Publication number: 20130109707
    Abstract: This invention relates to novel fluorouracil derivatives of Formula I or pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a thymidylate synthase inhibitor.
    Type: Application
    Filed: February 28, 2011
    Publication date: May 2, 2013
    Applicant: Concert Pharmaceuticals ,Inc.
    Inventors: Rose A. Persichetti, Julie F. Liu
  • Patent number: 8367674
    Abstract: This invention relates to novel compounds that are piperazine derivatives, and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel piperazine compounds that are derivatives of the chemokine CCR5 receptor antagonist, vicriviroc. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administering chemokine CCR5 receptor antagonists, such as vicriviroc. The invention also relates to the use of one or more of the disclosed compounds as reagents in analytical studies involving vicriviroc.
    Type: Grant
    Filed: April 17, 2009
    Date of Patent: February 5, 2013
    Assignee: CoNCERT Pharmaceuticals, Inc.
    Inventors: Julie F. Liu, Rose Persichetti
  • Patent number: 8357674
    Abstract: This invention relates to novel compounds which are derivatives of the phosphodiesterase inhibitor, cilostazol and pharmaceutically acceptable salts thereof. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administration of an phosphodiesterase inhibitor, such as cilostazol. The invention also relates to the use of the disclosed compounds and compositions as reagents in analytical studies involving cilostazol.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: January 22, 2013
    Assignee: CoNCERT Pharmaceuticals, Inc.
    Inventors: Julie F. Liu, Rose A. Persichetti
  • Patent number: 8349817
    Abstract: This invention relates to novel compounds which are derivatives of the phosphodiesterase inhibitor, cilostazol and pharmaceutically acceptable salts thereof. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administration of a phosphodiesterase inhibitor, such as cilostazol. The invention also relates to the use of the disclosed compounds and compositions as reagents in analytical studies involving cilostazol.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: January 8, 2013
    Assignee: CoNCERT Pharmaceuticals, Inc.
    Inventors: Rose A. Persichetti, Julie F. Liu, Craig E. Masse, Scott L. Harbeson
  • Publication number: 20120264721
    Abstract: This invention relates to novel compounds which are derivatives of the phosphodiesterase inhibitor, cilostazol and pharmaceutically acceptable salts thereof. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administration of an phosphodiesterase inhibitor, such as cilostazol. The invention also relates to the use of the disclosed compounds and compositions as reagents in analytical studies involving cilostazol.
    Type: Application
    Filed: June 29, 2012
    Publication date: October 18, 2012
    Applicant: CONCERT PHARMACEUTICALS, INC.
    Inventors: Julie F. Liu, Rose A. Persichetti
  • Publication number: 20120141513
    Abstract: This invention relates to novel compounds that are deuterated derivatives of fingolimod and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering a lysophospholipid edg1 (S1P1) receptor agonist, such as fingolimod.
    Type: Application
    Filed: December 5, 2011
    Publication date: June 7, 2012
    Inventors: Julie F. Liu, Rose A. Persichetti
  • Publication number: 20120058085
    Abstract: This invention relates to derivatives of 1-(p-chlorobenzyl)-2-(1-pyrrolidinylmethyl)benzimidazole according to Formula I wherein at least one Y is deuterium described herein and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of hepatitis C virus (HCV) RNA replication.
    Type: Application
    Filed: May 14, 2010
    Publication date: March 8, 2012
    Inventors: Rose A. Persichetti, Julie F. Liu, Adam Morgan
  • Publication number: 20110212944
    Abstract: This invention relates to novel 2-oxo-1-pyrrolidines, their derivatives, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a compound with the ability to act as a synaptic vesicle protein 2A (SV2A) ligand and/or a sodium channel blocker.
    Type: Application
    Filed: June 30, 2009
    Publication date: September 1, 2011
    Inventors: Julie Liu, Rose Persichetti
  • Publication number: 20100249079
    Abstract: This invention relates to novel compounds which are derivatives of the phosphodiesterase inhibitor, cilostazol and pharmaceutically acceptable salts thereof. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administration of a phosphodiesterase inhibitor, such as cilostazol. The invention also relates to the use of the disclosed compounds and compositions as reagents in analytical studies involving cilostazol.
    Type: Application
    Filed: December 22, 2009
    Publication date: September 30, 2010
    Inventors: Rose A. Persichetti, Julie F. Liu, Craig E. Masse, Scott L. Harbeson
  • Publication number: 20100120786
    Abstract: This invention relates to novel compounds that are piperazine derivatives, and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel piperazine compounds that are derivatives of the chemokine CCR5 receptor antagonist, vicriviroc. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administering chemokine CCR5 receptor antagonists, such as vicriviroc. The invention also relates to the use of one or more of the disclosed compounds as reagents in analytical studies involving vicriviroc.
    Type: Application
    Filed: October 21, 2009
    Publication date: May 13, 2010
    Applicant: CoNCERT Pharmaceuticals, Inc.
    Inventors: Julie F. Liu, Rose A. Persich├Ętti
  • Publication number: 20090270336
    Abstract: This invention relates to novel compounds that are piperazine derivatives, and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel piperazine compounds that are derivatives of the chemokine CCR5 receptor antagonist, vicriviroc. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administering chemokine CCR5 receptor antagonists, such as vicriviroc. The invention also relates to the use of one or more of the disclosed compounds as reagents in analytical studies involving vicriviroc.
    Type: Application
    Filed: April 17, 2009
    Publication date: October 29, 2009
    Applicant: CoNCERT Pharmaceuticals, Inc.
    Inventors: Julie F. Liu, Rose Persichetti
  • Publication number: 20090176744
    Abstract: This invention relates to novel compounds that are deuterated derivatives of fingolimod and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering a lysophospholipid edg1 (S1P1) receptor agonist, such as fingolimod.
    Type: Application
    Filed: October 31, 2008
    Publication date: July 9, 2009
    Applicant: CoNCERT Pharmaceuticals, Inc.
    Inventors: Julie F. Liu, Rose A. Persichetti
  • Patent number: 7528131
    Abstract: This disclosure relates to novel substituted morpholinyl compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a 5HT4 serotonin receptor agonist.
    Type: Grant
    Filed: April 18, 2008
    Date of Patent: May 5, 2009
    Assignee: Concert Pharmaceuticals Inc.
    Inventors: Rose A. Persichetti, Scott L. Harbeson
  • Publication number: 20090042842
    Abstract: This invention relates to novel compounds which are derivatives of the phosphodiesterase inhibitor, cilostazol and pharmaceutically acceptable salts thereof. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administration of an phosphodiesterase inhibitor, such as cilostazol. The invention also relates to the use of the disclosed compounds and compositions as reagents in analytical studies involving cilostazol.
    Type: Application
    Filed: April 24, 2008
    Publication date: February 12, 2009
    Applicant: CoNCERT Pharmaceuticals, Inc.
    Inventors: Julie F. Liu, Rose A. Persichetti
  • Publication number: 20080261983
    Abstract: This disclosure relates to novel substituted morpholinyl compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a 5HT4 serotonin receptor agonist.
    Type: Application
    Filed: April 18, 2008
    Publication date: October 23, 2008
    Applicant: CONCERT PHARMACEUTICALS INC.
    Inventors: Rose A. Persichetti, Scott L. Harbeson
  • Publication number: 20060223156
    Abstract: The present invention relates to crosslinked protein crystals characterized by the ability to change from insoluble and stable form to soluble and active form upon a change in the environment of said crystals, said change being selected from the group consisting of change in temperature, change in pH, change in chemical composition, change from concentrate to dilute form, change in oxidation-reduction potential of the solution, change in the incident radiation, change in transition metal concentration, change in flouride concentration, change in free radical concentration, change in metal chelater concentration, change in shear force acting upon the crystals and combinations thereof. According to one embodiment of this invention, such crosslinked protein crystals are capable of releasing their protein activity at a controlled rate.
    Type: Application
    Filed: December 19, 2005
    Publication date: October 5, 2006
    Inventors: Alexey Margolin, Rose Persichetti, Nancy St. Clair, Nazer Khalaf, Bhami Shenoy
  • Publication number: 20060104935
    Abstract: The present invention relates to crosslinked protein crystals characterized by the ability to change from insoluble and stable form to soluble and active form upon a change in the environment of said crystals, said change being selected from the group consisting of change in temperature, change in pH, change in chemical composition, change from concentrate to dilute form, change in shear force acting upon the crystals and combinations thereof. According to one embodiment of this invention, such crosslinked protein crystals are capable of releasing their protein activity at a controlled rate. This invention also provides methods for producing such crosslinked protein crystals, methods using them for protein delivery and methods using them in cleaning agents, including detergents, pharmaceutical compositions, vaccines, personal care compositions, including cosmetics, veterinary compositions, foods, feeds, diagnostics and formulations for decontamination.
    Type: Application
    Filed: January 6, 2006
    Publication date: May 18, 2006
    Inventors: Alexey Margolin, Rose Persichetti, Nancy St. Clair, Nazer Khalaf
  • Publication number: 20040202643
    Abstract: The present invention relates to crosslinked protein crystals characterized by the ability to change from insoluble and stable form to soluble and active form upon a change in the environment of said crystals, said change being selected from the group consisting of change in temperature, change in pH, change in chemical composition, change from concentrate to dilute form, change in shear force acting upon the crystals and combinations thereof. According to one embodiment of this invention, such crosslinked protein crystals are capable of releasing their protein activity at a controlled rate. This invention also provides methods for producing such crosslinked protein crystals, methods using them for protein delivery and methods using them in cleaning agents, including detergents, pharmaceutical compositions, vaccines, personal care compositions, including cosmetics, veterinary compositions, foods, feeds, diagnostics and formulations for decontamination.
    Type: Application
    Filed: January 16, 2004
    Publication date: October 14, 2004
    Applicant: Altus Biologics Inc.
    Inventors: Alexey L. Margolin, Rose A. Persichetti, Nancy L. St. Clair, Nazer K. Khalaf
  • Publication number: 20030211127
    Abstract: The present invention relates to crosslinked protein crystals characterized by the ability to change from insoluble and stable form to soluble and active form upon a change in the environment of said crystals, said change being selected from the group consisting of change in temperature, change in pH, change in chemical composition, change from concentrate to dilute form, change in oxidation-reduction potential of the solution, change in the incident radiation, change in transition metal concentration, change in flouride concentration, change in free radical concentration, change in metal chelater concentration, change in shear force acting upon the crystals and combinations thereof. According to one embodiment of this invention, such crosslinked protein crystals are capable of releasing their protein activity at a controlled rate.
    Type: Application
    Filed: January 2, 2003
    Publication date: November 13, 2003
    Inventors: Alexey L. Margolin, Rose A. Persichetti, Nancy L. St. Clair, Nazer K. Khalaf, Bhami C. Shenoy